Targeting Serotonin 2A and Adrenergic α
<sub>1</sub>
Receptors for Ocular Antihypertensive Agents: Discovery of 3,4‐Dihydropyrazino[1,2‐
<i>b</i>
]indazol‐1(2
<i>H</i>
)‐one Derivatives
作者:Guido Furlotti、Maria Alessandra Alisi、Nicola Cazzolla、Francesca Ceccacci、Beatrice Garrone、Tecla Gasperi、Angela La Bella、Francesca Leonelli、Maria Antonietta Loreto、Gabriele Magarò、Giorgina Mangano、Rinaldo Marini Bettolo、Emanuela Masini、Martina Miceli、Luisa Maria Migneco、Marco Vitiello
DOI:10.1002/cmdc.201800199
日期:2018.8.10
potential ocular hypotensive agents, we studied compounds that act on two receptors (serotonin 2A and adrenergic α1) linked to the regulation of aqueous humour dynamics. Herein we describe the design, synthesis, and pharmacological profiling of a series of novel bicyclic and tricyclic N2‐alkyl‐indazole‐amide derivatives. This study identified a 3,4‐dihydropyrazino[1,2‐b]indazol‐1(2H)‐one derivative with potent
青光眼影响着全球数百万人,并引起视神经损害和失明。眼内压升高(IOP)是与此病理相关的主要危险因素,而降低IOP是当前药物治疗的关键治疗目标。作为潜在的降眼压剂,我们研究的化合物,即对两个受体(血清素2A和肾上腺素能α行为1连接到房水动力学的调节)。在本文中,我们描述了一系列新型双环和三环N 2-烷基-吲唑酰胺衍生物的设计,合成和药理作用。这项研究确定了3,4-二氢吡嗪并[1,2 - b ]吲唑-1(2 H)具有强效的血清素2A受体拮抗作用-酮衍生物,>比其他血清素亚型受体100倍的选择性,而对于α高亲和力1受体。此外,相对于临床使用的参考化合物噻吗洛尔,在局部给药时,该化合物在体内显示出优异的眼降压作用。